Hangzhou Tianmushan Pharmaceutical Enterprise Co LtdSSE: 600671

Announcement on Convening the Q3 2025 Performance Briefing

Nov 6, 2025 · Issued by Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd via Shanghai Stock Exchange

Filed with SSE · Nov 6, 2025

On 6ix: 6ix.com/news/announcement-on-convening-the-q3-2025-performance-briefing-367

Announcement on Convening the Q3 2025 Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd on 6ix

Earlier from Hangzhou Tianmushan Pharmaceutical Enterprise

Announcement on the Termination of the Original Lease Contract of the Subsidiary’s Property, Signing of a New Lease Contract, and the Related Party TransactionOct 29, 2025
Announcement on Renewal of Drug Production LicenseSep 30, 2025
Announcement on Reply to Letter from Shanghai Stock Exchange on Information Disclosure and SupervisionSep 27, 2025
Announcement on Outline of the 2025 Semi-annual Performance BriefingSep 26, 2025
Announcement on Convening the 2025 Semi-annual Performance BriefingSep 17, 2025

Later from Hangzhou Tianmushan Pharmaceutical Enterprise

Announcement on Progress in Guarantees Provided to Subsidiaries and Guarantees Provided by SubsidiariesNov 12, 2025
Announcement on Expiration of the Plan for Issuance of Stocks to Specific ObjectsDec 6, 2025
Announcement on Obtaining Notice of Approval for Re-Registration of Drug by Wholly-owned SubsidiaryDec 19, 2025
Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025Dec 23, 2025
Announcement on Abnormal Fluctuations in Stock TradingJan 22

All Hangzhou Tianmushan Pharmaceutical Enterprise news releases

Follow Hangzhou Tianmushan Pharmaceutical Enterprise into a list and get an email when it puts out news.

Follow Hangzhou Tianmushan Pharmaceutical Enterprise